Table 2.
Patient background after propensity score matching
| Control group (34) | TACE group (34) | P | ||||
| Mean, SD | Median [IQR] | Mean, SD | Median [IQR] | |||
| Age (y) | 71.8, s = 6.7 | 72.5 [68–75] | 71.0, s = 8.5 | 72.5 [66.8–77.0] | 0.647 | |
| Prior treatment (%) | 11 (32) | 8 (24) | 0.588 | |||
| Gender (male; %) | 25 (74) | 30 (88) | 0.217 | |||
| BMI (kg/m2) | 23.6, s = 2.4 | 23.8 [22.2–25.2] | 23.1, s = 2.8 | 24.2 [20.6–25.4] | 0.457 | |
| Cause of hepatitis (%) | NBNC | 8 (24) | 4 (11) | 0.171 | ||
| HBV | 15 (38) | 10 (29) | ||||
| HCV | 10 (29) | 14 (41) | ||||
| Alcohol | 1 (3) | 5 (15) | ||||
| Other | 1 (3) | 3 (9) | ||||
| Child-Pugh score (%) | 5 | 27 (79) | 26 (76) | 0.765 | ||
| 6 | 6 (18) | 8 (24) | ||||
| 8 | 1 (3) | 0 | ||||
| Comorbidity (%) | Cardio-vascular disease | 5 (15) | 5 (15) | 1.000 | ||
| Diabetes | 9 (26) | 11 (32) | 0.796 | |||
| Creatinine (mg/dL) | 0.80, s = 0.23 | 0.76 [0.68–0.92] | 0.78, s = 0.13 | 0.8 [0.70–0.87] | 0.626 | |
| Albumin (g/dL) | 3.9, s = 0.4 | 4.0 [3.7–4.2] | 3.9, s = 0.42 | 3.9 [3.7–4.2] | 0.815 | |
| Bilirubin (mg/dL) | 0.70, s = 0.28 | 0.60 [0.53–0.88] | 0.68, s = 0.22 | 0.7 [0.5–0.8] | 0.663 | |
| AST (IU/L) | 40.1, s = 25.2 | 32 [26–48.3] | 37.8, s = 21.9 | 33 [26.8–39.0] | 0.602 | |
| ALT(IU/L) | 34.4, s = 26.0 | 24 [20–40.1] | 36.3, s = 24.7 | 30 [23.3–39.8] | 0.753 | |
| Cholinesterase (IU/L) | 205.1, s = 68.5 | 203.5[146–250.5] | 205.6, s = 80.0 | 191.5 [152.8–249.5] | 0.979 | |
| AFP (ng/mL) | 3342, s = 19120 | 5.8 [2.9–21.5] | 1251.4, s = 4445.4 | 10.1 [4.3–110] | 0.540 | |
| Platelet (/103μL) | 181.1, s = 51.8 | 180.5 [143–217.8] | 179.5, s = 80.7 | 172.5 [120.5–213] | 0.923 | |
| Prothrombin time (%) | 91.5, s = 14.6 | 91.4 [80.6–102] | 88.8, s = 9.8 | 90 [81–97.6] | 0.396 | |
| ICG-R15 (%) | 16.4, s = 6.6 | 14 [12–19.5] | 17.8, s = 13.9 | 15 [13–20] | 0.596 | |
| Extent of hepatic resection (%) | Non-anatomic | 15 (44) | 17 (50) | 0.724 | ||
| Segmentectomy | 7 (21) | 4 (12) | ||||
| Sectorectomy | 6 (18) | 7 (21) | ||||
| Lobe hepat-ectomy | 5 (15) | 8 (24) | ||||
| Hemi-hepat-ectomy | 5 (15) | 3 (9) | ||||
| Number of tumor (%) | 1 | 26 (76) | 25 (74) | 0.803 | ||
| 2 | 6 (18) | 8 (24) | ||||
| 3 | 2 (6) | 1 (3) | ||||
| Maximum diameter (mm) | 42.3, s = 35.7 | 27 [22–50] | 40.8, s = 30.0 | 30 [21.3–48.8] | 0.851 | |
| Histotype (%) | Well | 1 (3) | 3 (9) | 0.138 | ||
| Moderate | 32 (94) | 26 (76) | ||||
| Poor | 0 | 4 (12) | ||||
| NA | 1 (3) | 1 (3) | ||||
| Necrosis rate (%) | ≥ 90% | 12 (35) | ||||
| 89–50% | 4 (12) | |||||
| < 50% | 18 (53) | |||||
| Fibrosis stage* (%) | 0 | 4 (12) | 1 (3) | 0.515 | ||
| 1 | 8 (24) | 7 (21) | ||||
| 2 | 5 (15) | 8 (24) | ||||
| 3 | 3 (9) | 5 (15) | ||||
| 4 | 11 (32) | 8 (24) | ||||
*New Inuyama classification of chronic hepatitis. AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; ICG-R15, 15-minute retention rates of indocyanine green; IQR, interquartile range; NA, not available; NBNC, non-HBV non-HCV hepatitis; TACE, transcatheter arterial chemoembolization; y, year(s).